Waters A - Search Results

1

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.

Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, McMichael AJ, Rowland-Jones SL. Appay V, et al. Among authors: waters a. J Exp Med. 2000 Jul 3;192(1):63-75. doi: 10.1084/jem.192.1.63. J Exp Med. 2000. PMID: 10880527 Free PMC article.

2

Comparison between HIV- and CMV-specific T cell responses in long-term HIV infected donors.

Papagno L, Appay V, Sutton J, Rostron T, Gillespie GM, Ogg GS, King A, Makadzanhge AT, Waters A, Balotta C, Vyakarnam A, Easterbrook PJ, Rowland-Jones SL. Papagno L, et al. Among authors: waters a. Clin Exp Immunol. 2002 Dec;130(3):509-17. doi: 10.1046/j.1365-2249.2002.02005.x. Clin Exp Immunol. 2002. PMID: 12452843 Free PMC article.

3

CD4 responses to conserved HIV-1 T helper epitopes show both negative and positive associations with virus load in chronically infected subjects.

Boaz MJ, Waters A, Murad S, Easterbrook PJ, D'Sousa E, van Wheeley C, Vyakarnam A. Boaz MJ, et al. Among authors: waters a. Clin Exp Immunol. 2003 Dec;134(3):454-63. doi: 10.1111/j.1365-2249.2003.02307.x. Clin Exp Immunol. 2003. PMID: 14632751 Free PMC article.

4

HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression.

Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips RE; SPARTAC Trial Investigators. Frater J, et al. AIDS. 2014 Mar 13;28(5):699-708. doi: 10.1097/QAD.0000000000000130. AIDS. 2014. PMID: 24549145 Clinical Trial.

5

Does an HIV clinical trial information booklet improve patient knowledge and understanding of HIV clinical trials?

Ives NJ, Troop M, Waters A, Davies S, Higgs C, Easterbrook PJ. Ives NJ, et al. Among authors: waters a. HIV Med. 2001 Oct;2(4):241-9. doi: 10.1046/j.1464-2662.2001.00084.x. HIV Med. 2001. PMID: 11737404 Free article. Clinical Trial.

6

Epidemiological risk factors for hypersensitivity reactions to abacavir.

Easterbrook PJ, Waters A, Murad S, Ives N, Taylor C, King D, Vyakarnam A, Thorburn D. Easterbrook PJ, et al. Among authors: waters a. HIV Med. 2003 Oct;4(4):321-4. doi: 10.1046/j.1468-1293.2003.00166.x. HIV Med. 2003. PMID: 14525543 Free article.

7

Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators. Roberts HE, et al. PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb. PLoS Genet. 2015. PMID: 25642847 Free PMC article.

8

Modelling the evolution and spread of HIV immune escape mutants.

Fryer HR, Frater J, Duda A, Roberts MG; SPARTAC Trial Investigators; Phillips RE, McLean AR. Fryer HR, et al. PLoS Pathog. 2010 Nov 18;6(11):e1001196. doi: 10.1371/journal.ppat.1001196. PLoS Pathog. 2010. PMID: 21124991 Free PMC article.

9

HIV-1 DNA predicts disease progression and post-treatment virological control.

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators. Williams JP, et al. Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821. Elife. 2014. PMID: 25217531 Free PMC article.

10

Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991.

Easterbrook PJ, Hertogs K, Waters A, Wills B, Gazzard BG, Larder B. Easterbrook PJ, et al. Among authors: waters a. J Infect. 2002 Feb;44(2):88-91. doi: 10.1053/jinf.2002.0971. J Infect. 2002. PMID: 12076067

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,482 results

Search Page